{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:35:49Z","timestamp":1771022149748,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier","isbn-type":[{"value":"9780323855013","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.mcb.2021.08.001","type":"book-chapter","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:44:23Z","timestamp":1644453863000},"page":"1-14","source":"Crossref","is-referenced-by-count":3,"title":["High-efficiency of genetic modification using CRISPR\/Cpf1 system for engineered CAR-T cell therapy"],"prefix":"10.1016","member":"78","reference":[{"issue":"7","key":"10.1016\/bs.mcb.2021.08.001_bb0010","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/eji.1830230705","article-title":"New simplified molecular design for functional T cell receptor","volume":"23","author":"Brocker","year":"1993","journal-title":"European Journal of Immunology"},{"issue":"8","key":"10.1016\/bs.mcb.2021.08.001_bb0015","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"3","key":"10.1016\/bs.mcb.2021.08.001_bb0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41592-019-0329-7","article-title":"One-step generation of modular CAR-T cells with AAV\u2013Cpf1","volume":"16","author":"Dai","year":"2019","journal-title":"Nature Methods"},{"issue":"5","key":"10.1016\/bs.mcb.2021.08.001_bb0025","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cell.2019.07.044","article-title":"Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells","volume":"178","author":"Dong","year":"2019","journal-title":"Cell"},{"issue":"7643","key":"10.1016\/bs.mcb.2021.08.001_bb0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.mcb.2021.08.001_bb0035","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"The Journal of Immunology"},{"issue":"143","key":"10.1016\/bs.mcb.2021.08.001_bb0040","first-page":"1","article-title":"Production, purification, and quality control for adeno-associated virus-based vectors","author":"Fripont","year":"2019","journal-title":"Journal of Visualized Experiments"},{"key":"10.1016\/bs.mcb.2021.08.001_bb0045","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omtm.2017.04.007","article-title":"Development of a novel AAV gene therapy cassette with improved safety features and efficacy in a mouse model of Rett syndrome","volume":"5","author":"Gadalla","year":"2017","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"issue":"1","key":"10.1016\/bs.mcb.2021.08.001_bb0050","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1525-0016(03)00099-6","article-title":"Gene transfer into genomes of human cells by the sleeping beauty transposon system","volume":"8","author":"Geurts","year":"2003","journal-title":"Molecular Therapy"},{"issue":"24","key":"10.1016\/bs.mcb.2021.08.001_bb0055","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proceedings of the National Academy of Science"},{"key":"10.1016\/bs.mcb.2021.08.001_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Frontiers in Pharmacology"},{"issue":"7","key":"10.1016\/bs.mcb.2021.08.001_bb0065","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.mcb.2021.08.001_bb0070","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"The Journal of Clinical Investigation"},{"issue":"95","key":"10.1016\/bs.mcb.2021.08.001_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Science Translational Medicine"},{"issue":"S1","key":"10.1016\/bs.mcb.2021.08.001_bb0080","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/gb-2007-8-s1-s7","article-title":"Tol2: a versatile gene transfer vector in vertebrates","volume":"8","author":"Kawakami","year":"2007","journal-title":"Genome Biology"},{"issue":"12","key":"10.1016\/bs.mcb.2021.08.001_bb0085","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.mcb.2021.08.001_bb0090","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Molecular Therapy"},{"issue":"4","key":"10.1016\/bs.mcb.2021.08.001_bb0095","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1172\/JCI37630","article-title":"The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy","volume":"119","author":"Montini","year":"2009","journal-title":"The Journal of Clinical Investigation"},{"issue":"3","key":"10.1016\/bs.mcb.2021.08.001_bb0100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/21655979.2017.1282018","article-title":"Cas9, Cpf1 and C2c1\/2\/3\u2014What's next?","volume":"8","author":"Nakade","year":"2017","journal-title":"Bioengineered"},{"issue":"26","key":"10.1016\/bs.mcb.2021.08.001_bb0105","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/bs.mcb.2021.08.001_bb0110","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/hum.2016.040","article-title":"Advances in gene therapy for diseases of the eye","volume":"27","author":"Petit","year":"2016","journal-title":"Human Gene Therapy"},{"key":"10.1016\/bs.mcb.2021.08.001_bb0115","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1016\/bs.mcb.2021.08.001_bb0120","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nature Medicine"},{"issue":"374","key":"10.1016\/bs.mcb.2021.08.001_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1016\/bs.mcb.2021.08.001_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Scientific Reports"},{"issue":"5","key":"10.1016\/bs.mcb.2021.08.001_bb0135","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nature Reviews Drug Discovery"},{"issue":"6","key":"10.1016\/bs.mcb.2021.08.001_bb0140","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1111\/jcmm.15039","article-title":"The rapidly advancing class 2 CRISPR-Cas technologies: A customizable toolbox for molecular manipulations","volume":"24","author":"Wang","year":"2020","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"7","key":"10.1016\/bs.mcb.2021.08.001_bb0145","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","article-title":"Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor","volume":"180","author":"Wilkie","year":"2008","journal-title":"The Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.mcb.2021.08.001_bb0150","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.mt.6300028","article-title":"PiggyBac transposon-mediated gene transfer in human cells","volume":"15","author":"Wilson","year":"2007","journal-title":"Molecular Therapy"},{"issue":"10","key":"10.1016\/bs.mcb.2021.08.001_bb0155","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/mt.2012.194","article-title":"Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European Union","volume":"20","author":"Yl\u00e4-Herttuala","year":"2012","journal-title":"Molecular Therapy"},{"issue":"3","key":"10.1016\/bs.mcb.2021.08.001_bb0160","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","article-title":"Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system","volume":"163","author":"Zetsche","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.mcb.2021.08.001_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-017-1164-8","article-title":"Efficient precise knockin with a double cut HDR donor after CRISPR\/Cas9-mediated double-stranded DNA cleavage","volume":"18","author":"Zhang","year":"2017","journal-title":"Genome Biology"},{"issue":"1","key":"10.1016\/bs.mcb.2021.08.001_bb0170","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1038\/s41598-018-23803-7","article-title":"Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy","volume":"8","author":"Zhang","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.mcb.2021.08.001_bb0175","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and safety of CD28- or 4-1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Molecular Therapy\u2013Oncolytics"},{"issue":"12","key":"10.1016\/bs.mcb.2021.08.001_bb0180","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery","volume":"72","author":"Zufferey","year":"1998","journal-title":"Journal of Virology"}],"container-title":["Methods in Cell Biology","CAR T cells: development, characterization and applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X21000868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X21000868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:46:15Z","timestamp":1762231575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091679X21000868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323855013"],"references-count":35,"URL":"https:\/\/doi.org\/10.1016\/bs.mcb.2021.08.001","relation":{},"ISSN":["0091-679X"],"issn-type":[{"value":"0091-679X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}